Summary. Numerous studies have shown that coagulation abnormalities occur in the course of diabetes mellitus, resulting in a state of thrombophilia. These observations are supported by epidemiological studies which demonstrate that thromboembolic events are more likely to occur in diabetic patients. The coagulation abnormalities observed in diabetic patients seem to be caused by the hyperglycaemia, which also constitutes the distinguishing feature of this disease. These data are also supported by in vitro studies which demonstrate how glucose can directly determine alterations in the coagulation system. The abnormalities observed involve all stages of coagulation, affecting both thrombus formation and its inhibition, fibrinolysis, platelet and endothelial function. The final result is an imbalance between thrombus formation and dissolution, favouring the former. Hyperglycaemia probably determines the onset of these abnormalities through three mechanisms which are, respectively, non-enzymatic glycation, the development of increased oxidative stress and a decrease in the levels of heparan sulphate. The first seems to affect the functionality of key molecules of coagulation in a negative sense. Oxidative stress constitutes an important pro-thrombotic stimulus, while the decrease in heparan sulphate determines a reduction in antithrombotic defenses. Good metabolic control could play a key role in controlling the coagulation irregularities in diabetes. However, considering the difficulties in achieving such an objective, it is possible that the use of drugs may represent a valid alternative. In fact, several drugs exist which are of potential interest. It is, however, necessary to perform long-term studies which demonstrate unequivocably that by controlling the coagulation abnormalities in diabetic patients, prolongation of life is possible.
Patients suffering from diabetes mellitus have a high probability of developing acute cardiovascular disease, in particular myocardial infarct and cerebrovascular stroke [1] . This type of complication constitutes the cause of death in 80% of patients with Type2 (non-insulin-dependent) diabetes [1] . The development of cardiovascular disease is clearly linked with the onset of a thrombotic event: this is supported by numerous observations which report that in patients at risk for the development of cardiovascular events, a marked thrombophilia is present [2, 3] . Therefore in this regard, diabetic patients must be considered as a high risk group. However, diabetes per se is known to constitute an additional risk of developing cardiovascular disease [4] . Therefore it is reasonable to consider which is primarily responsible for the increased risk of thrombosis. Since hyperglycaemia is the distinguishing feature of diabetes, the hypothesis that it may constitute a key factor of hypercoagulability is suggestive. The aim of this work is to demonstrate the plausibility of this hypothesis and to examine the possible mechanisms by which hyperglycaemia could lead to the development of thrombophilia, with the consequent therapeutic implications.
Evidence of thrombophilia in diabetes
Good markers of thrombin activation are currently available which make it possible to show the existence of thrombophilia. Two very reliable markers are fibrinopeptide A (FPA) and the prothrombin fragment 1+2 (F1 + 2). These represent respectively, the amount of fibrinogen which is transformed into fibrin [5] and that of thrombin released in the circulation [6] . An increase of both FPA [7] and F1 + 2 [8] has been reported in diabetic patients, demonstrating the existence of a true thrombophilic diathesis. In the case of FPA, the increase is, moreover, directly correlated with hyperglycaemia, both in diabetic patients [9] and normal subjects in whom a hyper- glycaemic state has been artificially produced [10] . These data agree with the evidence of an increased fibrinogen turnover induced by the hyperglycaemia [11] .
Coagulation factors
The thrombin activation markers mentioned above represent the dynamic expression of the coagulation activation and thus certainly offer more information than a study of the individual factors which were widely investigated in diabetology, as summarized in Table 1 .
The most interesting coagulation factor is undoubtedly fibrinogen. Numerous epidemiological studies have concurred in recognizing it as having an important predictive value as a marker of cardiovascular risk [12] . Studies in diabetic patients seem to agree with these results [13, 14] .
Epidemiological studies have reported that high levels of factor VII are associated with a high mortality rate for cardiovascular events [15] . Increases in circulating factor VII have also been reported in diabetes [16] . In normal subjects, a direct correlation has been reported between levels of factor VII and fasting glycaemia [17] . In agreement with this is the demonstration that glycaemia levels can directly affect the concentrations of factor VII in both diabetic patients and normal subjects [16] .
The antigenic levels of factor X are also increased in diabetes [18] . The activation of this factor is however reduced by the induction of hyperglycaemia, which has been observed both in diabetic patients and in normal subjects [18] . This does not, however, result in reduced coagulation activation, which on the contrary, increases [18] . During hyperglycaemia, there is a simultaneous reduction in the functionality of antithrombin III (ATIII) which is the natural inhibitor of factor X. Thus the ratio between activated X and ATIII changes in favour of activated X, with the consequent onset of a state of hypercoagulability [18] .
Coagulation inhibitors
Since the action of thrombin is the result of a balance between the pro-coagulant cascade and the action of the various inhibitors on it or on its production, it is reasonable to assume that these inhibitors may also play an important role in the genesis of thrombophilia in diabetes.
One of the most studied inhibitors is ATIII. A decrease in the biological activity of this molecule in the presence of A. Ceriello: Thrombosis and diabetes meilitus a normal antigenic concentration has been found in diabetic patients [20] . In this case as well, hyperglycaemia seems capable of directly affecting the activity of the molecule, in both diabetic patients and in normal subjects [21, 22] . Confirming this observation, good metabolic control can increase the activity of the molecule [23, 24] . The effect of glycaemia on ATIII may have an important prothrombotic impact. In fact, its decreased biological activity results in a reduced thrombin-antithrombin complex formation with consequent hyperactivity of the thrombin [25] . Similar to ATIII, a reduction in biological activity, directly affected by metabolic control, has also been reported for heparin co-factor II, another plasma protease which inhibits thrombin [26] .
High levels of alpha-2-macroglobulin have been observed in diabetes [27] . Hyperglycaemia leads to an increase in this molecule, in both diabetic patients and normal subjects [28, 29] . Protein C is another important coagulation inhibitor. A decrease in protein C has been reported in diabetes [30] . This decrease is directly caused by hyperglycaemia, and affects the entire molecule, involving both the biological activity of the protein and its antigenic concentration [31] .
Protein S is an inhibitor that acts as a cofactor of activated protein C. Protein S circulates in plasma in two forms: one free and the other complexed with a fraction of the complement known as C4b-binding protein [32] . The biologically active form is the free one. A significant reduction of the latter has been reported in diabetes, due to an increase in the levels of C4b-binding protein which correlates with metabolic control [33] .
Platelets
The platelet alterations that occur in diabetes have been extensively studied. An increased platelet aggregation has been reported in Type 1 (insulin-dependent) diabetic patients with poor metabolic control [34] . This phenomenon is accompanied by an increase in the circulating levels of some indices of platelet activation such as fl-thromboglobulin [35] and platelet factor 4 [36] . The results on the production of thromboxane are, on the other hand, conflicting; an increase was reported in Type 1 and Type 2 diabetic patients, but seems to be affected by metabolic control only in the latter group [37, 38] [60] . The presence of microalbuminuria in diabetic patients has also been associated with an increase in plasma fibrinogen [61] .
Hypotheses on the pathogenetic mechanisms Fibrinolysis
Numerous studies have been published on the behaviour of fibrinolysis in diabetes, with frequently conflicting data [19] .
The role of hyperhasulinaemia in causing an increase in plasminogen activator inhibitor (PAI) is unclear. An association between hyperinsulinaemia and elevated PAI level in Type 2 diabetic patients has frequently been reported [49] . Evidence to date, however, does not indicate an effect of insulin on plasma PAI as these levels are usually normal in Type i diabetic patients taking insulin [50] and do not increase with its acute administration [49] . Since fibrinolysis, like coagulation, is a dynamic process, it cannot be studied in diabetic patients simply by evaluating the fibrinolytic parameters alone, but should be assessed by considering the balance between thrombus formation and fibrinolysis. This point of view is consistent with the data showing that fibrinolysis in diabetes is depressed, at least relative to the coagulation activation generally found [51] .
Lipoprotein (a)
Lipoprotein (a) (Lpa) at high levels has been associated with an increased risk of cardiovascular events [52] . An increase in Lpa in Type 1 diabetic subjects has been reported [53] . The most interesting fact is that its plasma levels seem to be correlated with the degree of metabolic control, varying according to the mean values of glycaemia [53].
Endothelium
It is now a well-known fact that the endothelium plays a key role in the regulation of haemostatic processes [54] . Human endothelial cells cultured under hyperglycaemic conditions demonstrate a whole series of prothrombotic alterations: a decreased production of prostacyclin [55], increased production of tissue factor [56] and an imbalance between the expression of tissue plasminogen activator and PAI favouring thrombosis [57] .
Microaibuminuria
An increased urinary excretion of albumin is significantly correlated with an increased incidence of mortality for cardiovascular events, in both Type 1 [58] and Type 2 From what has been described thus far, it seems clear that a series of abnormalities are present in diabetes which predispose the patient to development of a thrombotic event. This assumption is supported by epidemiological data [1] . Many of the described alterations seem to be dependent on glycaemic control. Therefore, it is feasible to consider how hyperglycaemia can cause a state of thrombophilia in diabetes.
Non-enzymatic glycation
One of the most accredited hypotheses on the pathogenesis of diabetic complications concerns the non-enzymatic glycation reactions which are capable of altering the functionality of a molecule.
This mechanism has been demonstrated in vitro for ATIII [62] . Glucose probably occupies the lysine residue which binds the ATIII to its natural cofactor, heparin, making the molecule less active [62] . This hypothesis was confirmed by the fact that both heparin and low molecular weight heparin are capable of preventing the alterations of the molecule induced by hyperglycaemia [63, 64] . Heparin co-factor II seems to have a similar fate, being actively glycated in vitro [65] .
The glycation mechanism seems to intervene at other levels. Fibrin may be glycated, thus becoming less sensitive to the processes of fibrinolysis [66] . Non-enzymatic glycation may also involve the platelet membrane proteins, reducing their fluidity and making them more sensitive to the thrombin pro-aggregant stimulus [67] . Glycation of the erythrocyte membranes also leads to a decrease in fluidity, with predictable repercussions on blood viscosity [68] . Finally, the advanced end-products of glycation, which derive from this reaction, may also be implicated in diabetic thrombophitia. It has, in fact, been demonstrated in vitro that cultured endothelial cells exposed to these products express a greater procoagulant activity [69] .
Oxidative stress
An increased oxidative stress has been established as present in diabetes [70] . The increase in production of free radicals is linked to processes of glucose auto-oxidation and to the possibility that the glycated proteins themselves release free radicals [71] . The production of free radicals is correlated to metabolic control and more directly to hyperglycaemia [72] . It is known that free radicals are capable of activating coagulation [73] , and direct evidence already exists which indicates that oxidative and thrombophilia in stress is accompanied by haemostatic alterations in diabetic patients [74] . On the basis of oxidative stress, the rapid inactivation of ATIII during induced hyperglycaemia [22] could also be included. The acute damage to the molecule could be due to a release of free radicals, since it has been demonstrated that oxidative stress is capable of reducing the activity of ATIII [75] .
Hyperglycaemia-mediated oxidative stress leads to a reduction in the erythrocytes' anti-oxidant defenses, in particular of vitamin E, inducing a procoagulant state [76] . These effects can be prevented by controlling the glycaemia [76] .
Reduced levels of vitamin E are reported in the platelets of diabetic subjects, accompanied by hyperaggregation [77] . Treatment with vitamin E improves this condition [77] .
Recent data demonstrate that oxidative stress mediated by hyperglycaemia affects some endothelial functions [78] . The finding in vivo that vitamin E improves the production of prostacyclin by the aortic endothelium would seem to confirm this point of view [79] .
Heparan sulphate
Another possible mechanism for the development of thrombophilia in diabetes is linked with the reduced synthesis of heparan sulphate [80] . Heparan sulphate is negatively charged and regulates the development of pericellular thrombotic phenomena at the level of the endothelial membrane, by interacting with ATIII [54] . It is therefore evident that a reduced synthesis of this glycosaminoglycan can lead to the appearance of thrombophilia. This hypothesis is supported by studies which reported an increased ratio between fibrinogen and ATIII, due to a decrease in ATIII [81] , in the aorta of diabetic rats and a general widespread reduction of the negative charges of the blood vessels in diabetic rats [82] . These observations confirm a reduced presence of glycosaminoglycans, and of heparan sulphate, in particular, on the endothelium. This reduction is largely due to a reduced endothelial synthesis [83] , and it is interesting to note that mesangial cells subjected to oxidative stress have been shown to selectively reduce the synthesis of heparan sulphate [84] .
Therapeutic approach
Currently many drugs are available for which their efficacy has been demonstrated in counteracting the coagulation alterations seen in diabetes, or which are potentially of use in this disease.
Anti-oxidants can probably be used. It has recently been demonstrated that vitamin E can normalise platelet function in Type 1 diabetic patients [85] . Anti-oxidants could also be used to control Lpa levels, an effect which has been demonstrated by acetylcysteine [86] . Sulphonylureas have demonstrated a platelet antiaggregant [87] and fibrinolysis stimulating effect [88] in vivo. Promising results have been obtained with a mixture of glycosaminoglycans, sulodexide. This was able to reduce fibrinogen and FPA levels [89] and to increase the profibrinolytic response during prothrombotic stimulation induced by hyperglycaemia [51] in diabetic patients. Bezafibrate has been shown to reduce fibrinogen levels in both Type 1 [90] and Type 2 diabetic patients [91] . Omega-3 fatty acids are also of interest. The use of these compounds has been associated with a reduced incidence of arteriosclerosis and cardiovascular events [92] . There are many indications for their use in the prevention of thrombotic complications in diabetes, since they seem to be able to reduce fibrinogen levels, improve platelet aggregation [93] and reduce Lpa levels [94] . Defibrotide is a polydeoxyribonucleotide with good antithrombotic and profibrinolytic potential linked to its anti-oxidant property [95] . In view of this it may be useful in the prevention of thrombosis in diabetes.
Conclusions
Diabetes is characterized by a series of alterations that undoubtably result in a thrombophilic state in patients with this disease. This is confirmed by epidemiological studies which indicate that diabetic patients more rapidly develop a thromboembolic event [1] . The series of studies quoted herein indicate that in a large number of cases hyperglycaemia might be the pathogenetic cause of thrombophilia. Hyperglycaemia, as summarized in Figure 1 , may act either by a mechanism connected with non-enzymatic glycation or by favouring an increased oxidative stress.
The presence of an alteration in glucose metabolism now seems to be a much more important cardiovascular risk factor than was previously assumed. This hypothesis is supported by the results of a number of studies. The Framingham study has shown that in non-diabetic women with an early cardiovascular event, the glycated haemoglobin levels were significantly above-normal [96] . Our preliminary studies in a cohort of normal subjects have shown that glycated haemoglobin correlates significantly with classic risk factors, such as hypertension and cholesterol [97] . On the other hand, both an increase in fi-brinogen [12] and oxidative stress [98] are now considered to be cardiovascular risk factors. It therefore seems that thrombophilic alterations can be considered as being strictly correlated with the poor regulation of the glucose metabolism, that these alterations probably have a pathogenetic value for cardiovascular events, and that oxidative stress may be the common determining factor.
A series of potentially valid therapeutic interventions to control thrombophilia in diabetic patients have been described. Long-term studies are indicated which demonstrate unequivocally that by correcting these coagulation irregularities, the life of diabetic patients can be prolonged. 
